Scholars Central

Conference abstractPublished 2 Nov 2015

The current landscape of myelodysplastic syndromes

Authors: Michael Keng

University of Virginia, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Myelodysplastic syndromes (MDS) are a heterogeneousgroup of clonal hematopoietic stem cell disorders characterized by cytopenias as a result of ineffective hematopoiesis and a propensity to progress to acute myeloid leukemia and premature mortality in many patients. MDS, especially lower-risk MDS, can be diagnostically challenging with substantial morphologic overlap with nutritional deficiencies, toxic injury, infections, and some inherited disorders. Recent studies have identified novel genetic changes, which help to provide a better understanding of the underlying pathobiology of MDS. This session will review how to distinguish lower-risk from higher-risk MDS, goals of therapy, and standard, non-transplant treatment approaches. The session will then build on these basics to highlight mechanistic-based approaches justifying novel monotherapies and combinations of drugs to treat lower-risk and higher-risk disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Michael Keng”